Vital rethinking in cancer early detection needed to save lives

On October 5, 2020 Cancer Research UK reported that Earlier detection of cancer offers arguably the single biggest opportunity to save lives from the disease, but there are many challenges of seeing this a reality for patients in the NHS, according to Cancer Research UK’s Roadmap for the Early Detection and Diagnosis of Cancer report, and highlighted in a commentary in the Lancet Oncology (Press release, Cancer Research UK, OCT 5, 2020, View Source [SID1234568131]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cancer Research UK’s consultation of over 100 experts highlights the siloed early detection research and development ecosystem, from academia and industry to the health services and policy makers, which is hampering progress. It proposes a series of tangible recommendations to unite these sectors, address these challenges and deliver a future where early detection of cancer is a routine reality.

Critically, it calls for the significant investment in diagnostic equipment and technologies, along with NHS staff, to support new ways of working and drive the paradigm shift to diagnose more cancers at an earlier stage, and ultimately save lives. The Roadmap also calls to attention a market failure in early detection of cancer, with too few innovative technologies making into the health system.

By having the right investments and policies in place, the UK has the potential to become a world leader in early detection and diagnosis of cancer, unlocking a major economic growth opportunity for the UK.

The authors hope that the prioritisation of early detection and diagnosis of cancer by scientists, companies, health services and government will create a thriving multidisciplinary ecosystem, focussed on proactively managing patients’ health and wellbeing before symptoms arise.

Dr David Crosby, head of prevention and early detection research at Cancer Research UK and co-author of the Roadmap said: "All too often, patients are being diagnosed at a late stage, where their cancer is deeply rooted and requires significant intervention, often with poor outcomes.

"This is a human tragedy, not just in terms of lives lost, but it also means more expensive treatments, hospital stays and monitoring. If we can turn this on its head and find cancer at its earliest stages when it’s easier to treat, not only will we be able to save lives on a vast scale, but we will be saving our NHS millions of pounds that would otherwise be needed for costly late stage treatments.

"For the first time, the Roadmap shows us how we can bring together the entire research, commercial and health ecosystem to create a future where lives are not needlessly lost due to late diagnosis."

Terry Kavanagh, who was diagnosed with lung cancer and took part in the consultation said: "I still remember the surgeon’s words after waking from surgery to remove half of my left lung, "Well Terry, I’m satisfied we caught it early". It’s why I’m still here. Taking part in the roadmap really opened my eyes to the number of disciplines that have to come together in a bigger plan to help other cancer patients. Hopefully one day, early detection will be a reality for every cancer."

Medivir appoints Dr. Tom Morris as interim Chief Medical Officer

On October 5, 2020 Medivir AB (Nasdaq Stockholm: MVIR) reported it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020 (Press release, Medivir, OCT 5, 2020, View Source [SID1234568130]). Dr. Morris will report to CEO Yilmaz Mahshid and join the Medivir Executive Team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tom Morris has more than 20 years of experience within drug development, mostly in oncology. Previously employed at Medeval Ltd and more recently at AstraZeneca. He has overseen the clinical development of several global drug programs, interacting with regulatory agencies, external clinical experts and academic groups worldwide.

Dr. Morris holds a BSc in Physiology from the University of Wales, medical degrees from the University of Wales College of Medicine and Master of Laws degree from Cardiff Law School. Currently a fellow and Board member of The Faculty of Pharmaceutical Medicine, a former chair of its Ethical Issues committee and a member of its Professional Standards Committee.

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2020

On October 5, 2020 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that it will release its financial results for the third quarter of 2020 before the market opens on Wednesday, October 21, 2020, and will hold a conference call on the same day at 8:30 a.m. EDT (Press release, Thermo Fisher Scientific, OCT 5, 2020, View Source [SID1234568129]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S. The conference ID is 1570827. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under "Financial Results." A replay of the call will be available under "Webcasts and Presentations" through Friday, November 6, 2020.

OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress – ESMO

On October 5, 2020 OncoHost, a global leader in host response profiling for improved personalized cancer therapy, reported that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion – Israel Institute of Technology, will deliver a presentation titled A Proteomics-Based Platform for Predicting Response to Immunotherapy and Personalizing Treatment Plans at the MAP 2020 Virtual Congress – ESMO (Free ESMO Whitepaper) this Friday, October 9th at 17:20 PM CEST (Press release, OncoHost, OCT 5, 2020, View Source;esmo-301145545.html [SID1234568128]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will show how through the analysis of host response profiles (i.e. the patient’s reaction), oncologists may be able to harness this information to better predict clinical outcomes and suggest the ideal combination treatment with immunotherapy.

"Despite major clinical success, immunotherapy treatments have demonstrated efficacy in only a small proportion of patients with non-small cell lung cancer (NSCLC)," said Prof. Yuval Shaked. "OncoHost’s studies have indicated that individual host response to anti-cancer treatment can generate pro-tumorigenic activities and support tumor re-growth and spread. It is therefore vital to analyze and earlier predict host response to treatment in order to improve outcomes and reduce unnecessary side effects experienced by so many patients."

Using machine learning (ML)-based analysis and algorithms to identify highly predictive cohort-based proteomic signatures in patients, personalized response prediction can be used to improve precision medicine in oncology. Personalized treatment plans can then be created through information based on cohort-based statistical analysis, personalized adaption and finally, translation to clinically relevant targets.

Prof. Shaked’s presentation will include a real-life case study on whom a Host Response profile analysis was performed, and will be followed by a live Q&A.

MAP is the leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration. This year’s event will be held virtually on October 9-10.

CARISMA Therapeutics to Participate in Upcoming Investor Conferences

On October 5, 2020 CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported that the company will present at two virtual investor conferences in October 2020 (Press release, Carisma Therapeutics, OCT 5, 2020, View Source [SID1234568127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan 4th Annual Genetic Medicines Conference
Tuesday, October 6, 2020 at 11:00 am EST
7th Solebury Trout Private Company Showcase Co-Hosted by BMO and Davis Polk
Thursday, October 15, 2020 at 10:40 am EST